5 Firms Build Migraine-Focused TriGemX's $600M SPAC Deal
By Jade Martinez-Pogue · October 19, 2026, 8:28 PM EDT
Biotechnology company TriGemX Bio on Monday unveiled plans to go public by merging with special purpose acquisition company TCGX Acquisition Corp. in a deal built by five law firms that creates...
To view the full article, register now.